On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Sarepta stock crashed Friday on reports the FDA will ask the biotech company to stop shipments of its approved gene therapy, ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

The Piper Sandler analysis comes as Sarepta navigates these emerging safety challenges with its DMD treatment, which has implications for both current administration protocols and potential future ...

Investing.com - Piper Sandler maintained its Neutral rating and $36.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) stock following safety concerns with its Duchenne muscular dystrophy (DMD) ...

H.C. Wainwright reiterated a 'Sell' rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.